The CRF1 receptor antagonist SSR125543 prevents stress-induced long-lasting sleep disturbances in a mouse model of PTSD: Comparison with paroxetine and d-cycloserine

Behavioural Brain Research

Volumn 279, Issue , 2015, Pages 41-46

  Philbert, Julie ^a   Beeské, Sandra ^a   Belzung, Catherine ^b   Griebel, Guy ^a  

^a SANOFI   (France)

^b UNIVERSITÉ DE TOURS   (France)

Author keywords

CRF1 receptor antagonist; D Cycloserine; Paroxetine; PTSD; Sleep disturbances; SSR125543; Stress

Indexed keywords

4 (2 CHLORO 4 METHOXY 5 METHYLPHENYL) N [2 CYCLOPROPYL 1 (3 FLUORO 4 METHYLPHENYL)ETHYL] 5 METHYL N (2 PROPYNYL) 2 THIAZOLAMINE; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; CYCLOSERINE; PAROXETINE; CORTICOTROPIN RELEASING FACTOR RECEPTOR; HALOGENATED HYDROCARBON; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; SEROTONIN UPTAKE INHIBITOR; THIAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL HOUSING; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; ELECTROENCEPHALOGRAPHY; MALE; MENTAL STRESS; MOUSE; NONHUMAN; NONREM SLEEP; POSTTRAUMATIC STRESS DISORDER; REM SLEEP; SLEEP DISORDER; SLEEP PATTERN; SLEEP TIME; TREATMENT DURATION; WAKEFULNESS; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN; COMPLICATION; DRUG EFFECTS; ELECTRIC SHOCK; PATHOPHYSIOLOGY; PHYSIOLOGY; SLEEP; SLEEP DISORDERS; SLEEP WAKE DISORDERS;

ANIMALS; BRAIN; CYCLOSERINE; DISEASE MODELS, ANIMAL; ELECTROENCEPHALOGRAPHY; ELECTROSHOCK; HYDROCARBONS, HALOGENATED; MALE; MICE; PAROXETINE; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; RECEPTORS, N-METHYL-D-ASPARTATE; SEROTONIN UPTAKE INHIBITORS; SLEEP; SLEEP DISORDERS; SLEEP WAKE DISORDERS; STRESS DISORDERS, POST-TRAUMATIC; STRESS, PSYCHOLOGICAL; THIAZINES; WAKEFULNESS;

EID: 84911898784     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2014.11.006     Document Type: Article

References (39)

1. Lavie P. Sleep disturbances in the wake of traumatic events. N Engl J Med 2001, 345(25):1825-1832.
2. Spoormaker V.I., Montgomery P. Disturbed sleep in post-traumatic stress disorder: secondary symptom or core feature?. Sleep Med Rev 2008, 12(3):169-184.
3. Meewisse M.L., Nijdam M.J., de Vries G.J., Gersons B.P., Kleber R.J., van d V., et al. Disaster-related posttraumatic stress symptoms and sustained attention: evaluation of depressive symptomatology and sleep disturbances as mediators. J Trauma Stress 2005, 18(4):299-302.
4. Belleville G., Guay S., Marchand A. Impact of sleep disturbances on PTSD symptoms and perceived health. J Nerv Ment Dis 2009, 197(2):126-132.
5. Nappi C.M., Drummond S.P., Hall J.M. Treating nightmares and insomnia in posttraumatic stress disorder: a review of current evidence. Neuropharmacology 2012, 62(2):576-585.
6. Maher M.J., Rego S.A., Asnis G.M. Sleep disturbances in patients with post-traumatic stress disorder: epidemiology, impact and approaches to management. CNS Drugs 2006, 20(7):567-590.
7. Baker D.G., West S.A., Nicholson W.E., Ekhator N.N., Kasckow J.W., Hill K.K., et al. Serial CSF corticotropin-releasing hormone levels and adrenocortical activity in combat veterans with posttraumatic stress disorder. Am J Psychiatry 1999, 156(4):585-588.
8. Bremner J.D., Licinio J., Darnell A., Krystal J.H., Owens M.J., Southwick S.M., et al. Elevated CSF corticotropin-releasing factor concentrations in posttraumatic stress disorder. Am J Psychiatry 1997, 154(5):624-629.
9. de Kloet C.S., Vermetten E., Geuze E., Lentjes E.G., Heijnen C.J., Stalla G.K., et al. Elevated plasma corticotrophin-releasing hormone levels in veterans with posttraumatic stress disorder. Prog Brain Res 2008, 167:287-291.
10. Sapolsky R.M., McEwen B.S. Down-regulation of neural corticosterone receptors by corticosterone and dexamethasone. Brain Res 1985, 339(1):161-165.
11. de Kloet E.R. Stress in the brain. Eur J Pharmacol 2000, 405(1-3):187-198.
12. Opp M.R. Rat strain differences suggest a role for corticotropin-releasing hormone in modulating sleep. Physiol Behav 1997, 63(1):67-74.
13. Tang X., Xiao J., Liu X., Sanford L.D. Strain differences in the influence of open field exposure on sleep in mice. Behav Brain Res 2004, 154(1):137-147.
14. Liu X., Wellman L.L., Yang L., Ambrozewicz M.A., Tang X., Sanford L.D. Antagonizing corticotropin-releasing factor in the central nucleus of the amygdala attenuates fear-induced reductions in sleep but not freezing. Sleep 2011, 34(11):1539-1549.
15. Held K., Kunzel H., Ising M., Schmid D.A., Zobel A., Murck H., et al. Treatment with the CRH1-receptor-antagonist R121919 improves sleep-EEG in patients with depression. J Psychiatr Res 2004, 38(2):129-136.
16. 1 receptor antagonist SSR125543 attenuates long-term cognitive deficit induced by acute inescapable stress in mice, independently from the hypothalamic pituitary adrenal axis. Pharmacol Biochem Behav 2012, 102(3):415-422.
17. 1 receptor antagonist SSR125543 prevents stress-induced cognitive deficit associated with hippocampal dysfunction: comparison with paroxetine and d-cycloserine. Psychopharmacology (Berl) 2013, 228(1):97-107.
18. Philbert J., Pichat P., Beeske S., Decobert M., Belzung C., Griebel G. Acute inescapable stress exposure induces long-term sleep disturbances and avoidance behavior: a mouse model of post-traumatic stress disorder (PTSD). Behav Brain Res 2011, 221(1):149-154.
19. Bonnet MH. Sleep fragmentation. In: Lenfant C, editor. Sleep Deprivation. New York: Marcel Dekker; 2005. p. 103-17.
20. Bonnet M.H. Sleep restoration as a function of periodic awakening, movement, or electroencephalographic change. Sleep 1987, 10(4):364-373.
21. Stepanski E.J. The effect of sleep fragmentation on daytime function. Sleep 2002, 25(3):268-276.
22. Tartar J.L., Ward C.P., McKenna J.T., Thakkar M., Arrigoni E., McCarley R.W., et al. Hippocampal synaptic plasticity and spatial learning are impaired in a rat model of sleep fragmentation. Eur J Neurosci 2006, 23(10):2739-2748.
23. Stein D.J., Davidson J., Seedat S., Beebe K. Paroxetine in the treatment of post-traumatic stress disorder: pooled analysis of placebo-controlled studies. Expert Opin Pharmacother 2003, 4(10):1829-1838.
24. Sheehan D., Beebe K.L., Dube E.M. Paroxetine for the treatment of sleep disturbance in posttraumatic stress disorder. Euro Neuropsychopharmacol 2002, 12(Suppl. 3):356.
25. Litz B.T., Salters-Pedneault K., Steenkamp M.M., Hermos J.A., Bryant R.A., Otto M.W., et al. A randomized placebo-controlled trial of d-cycloserine and exposure therapy for posttraumatic stress disorder. J Psychiatr Res 2012, 46(9):1184-1190.
26. Ressler K.J., Rothbaum B.O., Tannenbaum L., Anderson P., Graap K., Zimand E., et al. Cognitive enhancers as adjuncts to psychotherapy: use of d-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry 2004, 61(11):1136-1144.
27. Hofmann S.G., Pollack M.H., Otto M.W. Augmentation treatment of psychotherapy for anxiety disorders with d-cycloserine. CNS Drug Rev 2006, 12(3-4):208-217.
28. de Kleine R.A., Hendriks G.J., Kusters W.J., Broekman T.G., van M.A. A randomized placebo-controlled trial of d-cycloserine to enhance exposure therapy for posttraumatic stress disorder. Biol Psychiatry 2012, 71(11):962-968.
29. Difede J., Cukor J., Wyka K., Olden M., Hoffman H., Lee F.S., et al. d-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: a pilot randomized clinical trial. Neuropsychopharmacology 2014, 39(5):1052-1058.
30. Rodrigues H., Figueira I., Lopes A., Goncalves R., Mendlowicz M.V., Coutinho E.S., et al. Does d-cycloserine enhance exposure therapy for anxiety disorders in humans? A meta-analysis. PLoS One 2014, 9(7):e93519.
31. Rothbaum B.O., Price M., Jovanovic T., Norrholm S.D., Gerardi M., Dunlop B., et al. A randomized, double-blind evaluation of D-cycloserine or alprazolam combined with virtual reality exposure therapy for posttraumatic stress disorder in Iraq and Afghanistan War veterans. Am J Psychiatry 2014, 171(6):640-648.
32. Ledgerwood L., Richardson R., Cranney J. D-cycloserine and the facilitation of extinction of conditioned fear: consequences for reinstatement. Behav Neurosci 2004, 118(3):505-513.
33. Ledgerwood L., Richardson R., Cranney J. D-cycloserine facilitates extinction of learned fear: effects on reacquisition and generalized extinction. Biol Psychiatry 2005, 57(8):841-847.
34. Yamamoto S., Morinobu S., Fuchikami M., Kurata A., Kozuru T., Yamawaki S. Effects of single prolonged stress and D-cycloserine on contextual fear extinction and hippocampal NMDA receptor expression in a rat model of PTSD. Neuropsychopharmacology 2008, 33(9):2108-2116.
35. Wellman L.L., Yang L., Tang X., Sanford L.D. Contextual fear extinction ameliorates sleep disturbances found following fear conditioning in rats. Sleep 2008, 31(7):1035-1042.
36. Gupta S.C., Hillman B.G., Prakash A., Ugale R.R., Stairs D.J., Dravid S.M. Effect of D-cycloserine in conjunction with fear extinction training on extracellular signal-regulated kinase activation in the medial prefrontal cortex and amygdala in rat. Eur J Neurosci 2013, 37(11):1811-1822.
37. Romanowski C.P., Fenzl T., Flachskamm C., Wurst W., Holsboer F., Deussing J.M., et al. Central deficiency of corticotropin-releasing hormone receptor type 1 (CRH-R1) abolishes effects of CRH on NREM but not on REM sleep in mice. Sleep 2010, 33(4):427-436.
38. Gully D., Geslin M., Serva L., Fontaine E., Roger P., Lair C., et al. 4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylp henyl)ethyl]5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine hydrochloride (SSR125543A): a potent and selective corticotrophin-releasing factor(1) receptor antagonist. I. Biochemical and pharmacological characterization. J Pharmacol Exp Ther 2002, 301(1):322-332.
39. Kimura M., Muller-Preuss P., Lu A., Wiesner E., Flachskamm C., Wurst W., et al. Conditional corticotropin-releasing hormone overexpression in the mouse forebrain enhances rapid eye movement sleep. Mol Psychiatry 2010, 15(2):154-165.